Alexion Pharma (ALXN) Tops Q1 EPS by 51c, Lowers FY20 Guiadnce

Alexion Pharma (NASDAQ: ALXN) reported Q1 EPS of $3.22, $0.51 better than the analyst estimate of $2.71. Revenue for the quarter came in at $1.44 billion versus the consensus estimate of $1.36 billion.

GUIDANCE:

Alexion Pharma sees 2020 EPS of $10.45-$10.75, versus the consensus of $11.01. Alexion Pharma sees 2020 revenue of $5.23-5.33 billion, versus the consensus of $5.6 billion.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• CalPrivate Bank names Andra Frazier as chief credit officer